Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma

Table 2 Analysis for the risk factors of mortality n (%)

Variables	Mortality (n = 41)	Survival (n = 88)	P value
Male	27 (66)	65 (74)	0.405
Age (yr)	60.9 ± 9.8	60.9 ± 11.2	0.956
Alcohol history	23 (56)	52 (59)	0.846
Smoking history	29 (71)	59 (67)	0.835
Presence of cirrhosis	37 (90)	77 (88)	0.772
BCLC class (A0/A1)	7/34	33/55	0.024
Number of nodule	36/2/3	79/8/1	0.129
Number of feeding vessel (1/2/≥ 3)	34/0/7	64/1/23	0.471
Child-Pugh score	6.1 ± 1.0	5.6 ± 0.9	0.013
Greatest diameter of nodule (cm)	2.5 ± 1.0	2.3 ± 1.1	0.383
Number of TACE treatment	3.3 ± 2.5	2.2 ± 2.0	0.010
Amount of doxorubicin used (mg)	29.4 ± 13.2	25.9 ± 12.4	0.156
Amount of lipiodol used (mL)	7.3 ± 3.7	5.9 ± 3.4	0.041
Presence of arterio-venous shunt	9 (20)	9 (10)	0.284
Use of gelatin sponge	21 (51)	35 (40)	0.239
Complete lipiodol uptake	31 (76)	63 (72)	0.492
Sub-segmental approach of catheter	32 (78)	66 (75)	0.624
Extrahepatic collateral supply	1 (2)	2 (2)	1.000
Visible hepatic vein during TACE	34 (83)	73 (83)	0.711

BCLC: Barcelona Clinic Liver Cancer; TACE: Transarterial chemoembolization.